Single Dose Pharmacokinetics of Repaglinide, Metformin and Combination Tablet in Fed Healthy Volunteers

Inclusion Criteria:

- Healthy male and female volunteers (female not pregnant, lactating or breastfeeding)

- BMI (Body Mass Index) between 19-29 kg/m^2, both inclusive

- Fasting plasma glucose from 70-115 mg/dl

- Subject is judged to be in good health on the basis of their medical history,
physical examination, ECG (electrocardiogram), and routine laboratory data

Exclusion Criteria:

- Any clinically significant disease history, in the opinion of the Investigator, of
systemic or organ disease

- Clinically significant abnormalities on pre-study clinical examination or any
laboratory measurements during screening

- Positive results on screening for Hepatitis B surface antigen, Hepatitis C antibody
and HIV (human immunodeficiency virus) antibody

- Positive results on the drug abuse/alcohol screen

- Any regular use of prescription or nonprescription drugs, including mega-vitamin or
herbal supplement regimens, other than contraceptives, that cannot be stopped at
least 1 week prior to Visit 2 (trial product dose administration) and for the
duration of the study

- Subject is currently a smoker (more than one cigarette per day or equivalent)

- Use of grapefruit or grapefruit juice within 7 days of trial product dose
administration

- Blood donation, surgery or trauma with significant blood loss (500 mL) within the
last 2 months prior to dosing